Pay in 4 interest-free payments of $7.05 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Verify that insurance acceptance and prior authorization support are part of the offerings
Personalized GLP-1 Therapy: Why Genetic Testing Matters The PlexusDx Precision Peptide Genetic Test analyzes GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) variants that relate to GLP-1 and related signaling pathways
Additionally, other genetic variants and environmental factors can affect your methylation and overall health
While access remains uneven across commercial plans and Medicare coverage for obesity medicines is still limited, CVS decision signals continued normalization of GLP-1 therapies within mainstream pharmacy benefit design and intensifies competition between Lilly and Novo Nordisk for long-term market leadership in obesity careTop of FormBottom of Form Sources CVS brings back coverage for Lilly's obesity drug Zepbound Reuters May 28, 2026 Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge Reuters May 1, 2025
Let us help you restore your health and vitality with proven, effective treatments that deliver real results
In the second hour, peak GLP-1 concentrations were maintained in healthy participants, but returned to lower levels in type 2 diabetic patients
US$ 24.61
US$ 26.80
US$ 23.92
US$ 28.05
US$ 24.33
US$ 20.30
US$ 24.95
US$ 25.75
